Kubacka Monika, Mogilski Szczepan, Zadrożna Monika, Nowak Barbara, Szafarz Małgorzata, Pomierny Bartosz, Marona Henryk, Waszkielewicz Anna, Jawień Wojciech, Sapa Jacek, Bednarski Marek, Knutelska Joanna, Kotańska Magdalena
Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688 Kraków, Poland.
Department of Cytobiology, Faculty of Pharmacy, Medical College, Jagiellonian University, Medyczna 9, 30-688 Kraków, Poland.
Pharmaceuticals (Basel). 2021 May 18;14(5):477. doi: 10.3390/ph14050477.
Quinazoline α-adrenoceptors antagonists have been shown to exert moderately favorable effects on the metabolic profile in hypertensive patients. However, based on AntiHypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) results, they are no longer recommended as a first line therapy of hypertension. Recent studies have shown that quinazoline-based α-adrenoceptors antagonists (prazosin, doxazosin) induce the apoptosis and necrosis, which may be responsible for ALLHAT outcomes; however, these effects were proven to be independent of α-adrenoceptor blockade and were associated with the presence of quinazoline moiety. MH-76 (1-[3-(2,6-dimethylphenoxy)propyl]-4-(2-methoxyphenyl)piperazine hydrochloride)) is a non-quinazoline α-adrenoceptor antagonist which, in fructose-fed rats, exerted antihypertensive effect, and, contrary to prazosin, reduced insulin resistance and abdominal adiposity. In this study we aimed to further investigate and compare the effects of MH-76 and prazosin on inflammation in adipose tissue of fructose-fed rats.
Abdominal adipose tissue was collected from four groups of fructose-fed rats (Control, Fructose, Fructose + MH-76 and Fructose + Prazosin) and subjected to biochemical, histopathological and immunohistochemical studies. Moreover, selected tissue distribution studies were performed.
Treatment with MH-76 but not with prazosin improved endothelial integrity, reduced adipose tissue inflammation and infiltration by immune cells, resulting in lowering leptin, MCP-1, IL-6, TNF-α and PAI-1 levels. In adipose tissue from Fructose + MH-76 animals, a higher amount of eosinophils accompanied with higher IL-4 concentration was observed. Treatment with MH-76 but not with prazosin markedly reduced phosphorylation of IRS-1 at Ser307.
MH-76 may improve insulin signaling in adipose tissue by reducing the pro-inflammatory cytokine production and inhibiting the inflammatory cells recruitment. In contrast, in adipose tissue from animals treated with prazosin, the inflammatory effect was clearly enhanced.
喹唑啉α-肾上腺素能受体拮抗剂已被证明对高血压患者的代谢状况有一定的有利影响。然而,根据抗高血压和降脂治疗预防心脏病发作试验(ALLHAT)的结果,它们不再被推荐作为高血压的一线治疗药物。最近的研究表明,基于喹唑啉的α-肾上腺素能受体拮抗剂(哌唑嗪、多沙唑嗪)可诱导细胞凋亡和坏死,这可能是ALLHAT结果的原因;然而,这些作用被证明独立于α-肾上腺素能受体阻断,并且与喹唑啉部分的存在有关。MH-76(1-[3-(2,6-二甲基苯氧基)丙基]-4-(2-甲氧基苯基)哌嗪盐酸盐)是一种非喹唑啉α-肾上腺素能受体拮抗剂,在喂食果糖的大鼠中具有降压作用,与哌唑嗪相反,它可降低胰岛素抵抗和腹部肥胖。在本研究中,我们旨在进一步研究和比较MH-76和哌唑嗪对喂食果糖大鼠脂肪组织炎症的影响。
从四组喂食果糖的大鼠(对照组、果糖组、果糖+MH-76组和果糖+哌唑嗪组)收集腹部脂肪组织,并进行生化、组织病理学和免疫组织化学研究。此外,还进行了选定的组织分布研究。
用MH-76治疗而非哌唑嗪治疗可改善内皮完整性,减少脂肪组织炎症和免疫细胞浸润,从而降低瘦素、MCP-1、IL-6、TNF-α和PAI-1水平。在果糖+MH-76组动物的脂肪组织中,观察到较高数量的嗜酸性粒细胞伴随着较高的IL-4浓度。用MH-76治疗而非哌唑嗪治疗可显著降低IRS-1在Ser307处的磷酸化。
MH-76可能通过减少促炎细胞因子的产生和抑制炎症细胞募集来改善脂肪组织中的胰岛素信号。相比之下,在接受哌唑嗪治疗的动物的脂肪组织中,炎症作用明显增强。